Regentis Biomaterials Ltd. 6-K Filing
Ticker: RGNT · Form: 6-K · Filed: Dec 5, 2025 · CIK: 1912966
| Field | Detail |
|---|---|
| Company | Regentis Biomaterials Ltd. (RGNT) |
| Form Type | 6-K |
| Filed Date | Dec 5, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $8.00, $10 m |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Regentis Biomaterials Ltd. (ticker: RGNT) to the SEC on Dec 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $8.00 (at an initial public offering price of $8.00 per Ordinary Share. In connection with); $10 m (gregate gross proceeds of approximately $10 million, before deducting underwriting di).
How long is this filing?
Regentis Biomaterials Ltd.'s 6-K filing is 1 pages with approximately 440 words. Estimated reading time is 2 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2025-12-05 16:15:27
Key Financial Figures
- $8.00 — at an initial public offering price of $8.00 per Ordinary Share. In connection with
- $10 m — gregate gross proceeds of approximately $10 million, before deducting underwriting di
Filing Documents
- ea0268586-6k_regentis.htm (6-K) — 14KB
- ea026858601ex1-1_regentis.htm (EX-1.1) — 319KB
- ea026858601ex99-1_regentis.htm (EX-99.1) — 13KB
- ea026858601ex99-2_regentis.htm (EX-99.2) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- ex99-2_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-118725.txt ( ) — 392KB
Underwriting
Underwriting Agreement, dated as of December 3, 2025, by and between the Company and ThinkEquity LLC 99.1 Press release titled: “Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering”. 99.2 Press release titled: “Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering”. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Regentis Biomaterials Ltd. Date: December 5, 2025 By: /s/ Dr. Eli Hazum Name: Dr. Eli Hazum Title: Chief Executive Officer 3